Roche, Novartis slam Italian cartel fine
This article was originally published in Scrip
Executive Summary
Roche and Novartis have reacted angrily to a decision by the Italian Competition Authority to fine them €182.5m for what it described as "illicit collusion" to exclude Roche's Avastin from the ophthalmology market in favor of Novartis's similar drug Lucentis.
You may also be interested in...
EU Avastin Court Ruling Deals Yet Another Blow To Novartis
In the latest in a string of knockbacks for both Novartis and Roche, the EU’s highest court has said that the Italian authorities are within their rights to reimburse Roche’s Avastin for wet AMD, even though it is not approved for that indication.
Another Knockback For Roche And Novartis As CJEU Rules On Italian Competition Case
In the latest development in the long-running case pitting Novartis and Roche against the Italian competition authority over a fine imposed in 2014, the Court of Justice of the EU has confirmed that the firms’ arrangement over Avastin and Lucentis could constitute a serious restriction on competition if it involved the dissemination of misleading information. The case now goes back to the Italian court.
20 Voices: What Does 2024 Hold For Biopharma?
20 executives in the biopharma industry outline their view of key trends this year. A selection of commentary from a broad industry survey by Scrip.